NCCN | GenomeWeb

NCCN

The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.

The network said MDxHealth's ConfirmMDx should be used to screen men at higher risk for prostate cancer despite a negative biopsy. 

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has included two molecular diagnostics – Myriad Genetics' Prolaris and Genomic Health's Oncotype DX Prostate Cancer – in its most recent guidelines for the disease, noting that these two assays "appear further along in development a

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has approved inclusion of Biodesix's VeriStrat proteomics test in its guidelines for non-small cell lung cancer, the Boulder, Colo.-based firm said today.

The National Comprehensive Cancer Network now supports MGMT methylation testing in elderly glioblastoma patients to assess the likelihood that they will benefit from temozolomide treatment. This may help spur adoption of MDxHealth's MGMT PredictMDx for Glioblastoma test.

This article has been updated to correct that Ellen Matloff is a plaintiff in AMP v. USPTO.

After garnering a CLIA-certified clinical laboratory through its purchase of Navigenics last week, Life Technologies wasted no time jumping into the molecular diagnostics space.

Genomic Health discussed the status of its ongoing work with Pfizer in renal cancer and suggested it might eventually develop a companion test for Erbitux that gauges mutations "beyond KRAS."

Pages

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.